Eric Bjerkholt - 06 Jul 2026 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
08 Jul 2026, 17:07:31 UTC
Prior SEC filing
11 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Eric Bjerkholt filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 08 Jul 2026.

Key facts

  • This page summarizes Eric Bjerkholt's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
  • 4 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 08 Jul 2026, 17:07.

Change

  • Previous filing in this sequence was filed on 11 Jun 2026.
  • Current net transaction value: -$611,273.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001197350 Primary reporting owner

BJERKHOLT ERIC

Relationship
CHIEF FINANCIAL OFFICER
Address
C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Signature date
08 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Sale

Transaction value
$380,097
Shares
-3,124
Change %
-6.6%
Price
$121.67
Shares after
44,057
Date
06 Jul 2026
Ownership
Direct
Footnotes
F1, F2
MIRM transaction

Common Stock

Sale

Transaction value
$128,307
Shares
-1,048
Change %
-2.4%
Price
$122.43
Shares after
43,009
Date
06 Jul 2026
Ownership
Direct
Footnotes
F1, F3
MIRM transaction

Common Stock

Sale

Transaction value
$65,388
Shares
-528
Change %
-1.2%
Price
$123.84
Shares after
42,481
Date
06 Jul 2026
Ownership
Direct
Footnotes
F1, F4
MIRM transaction

Common Stock

Sale

Transaction value
$37,482
Shares
-300
Change %
-0.71%
Price
$124.94
Shares after
42,181
Date
06 Jul 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.

Footnote F2

. The weighted average sale price for the transaction reported was $121.67, and the range of prices were between $121.13 and $122.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

. The weighted average sale price for the transaction reported was $122.43, and the range of prices were between $122.235 and $123.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F4

. The weighted average sale price for the transaction reported was $123.84, and the range of prices were between $123.285 and $124.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .